I’m not a financial advisor; Superpowers for Good should not be considered investment advice. Seek counsel before making investment decisions. This episode is sponsored by 20/20 GeneSystems.
Today, we’re sharing a special LIVE episode of the Superpowers for Good, Streaming at 6:30 PM Eastern Time on e360tv, Facebook, LinkedIn, and YouTube. You can watch it directly in the YouTube player embedded in this post. Join us as we welcome Jonathan Cohen, CEO of 20/20 GeneSystems, to discuss their pioneering Cancer detection Technology. With their Wefunder campaign closing this Friday, this is a critical opportunity to learn more, ask questions live, and explore the company’s exciting future.
Keep reading to learn:
Why Watch – Discover the top reasons to tune in, including live audience engagement, exclusive investment insights, and the company’s ambitious plans.
What Makes 20/20 GeneSystems So Exciting – Learn how their groundbreaking multi-cancer detection technology is making early screening more accessible and affordable.
Why You Should Consider Investing in the Future of Cancer Detection – Understand why this company is making waves in healthcare and why now may be the time to explore an investment.
Today’s special live episode of Superpowers for Good is a must-watch event! We’re sitting down with Jonathan Cohen, CEO of 20/20 GeneSystems, for an in-depth discussion about their groundbreaking cancer detection technology—and you can join us live.
Here’s why you won’t want to miss it:
Ask Questions in Real Time – Engage directly with Jonathan Cohen and get your questions answered live.
Exclusive Investment Insights – Gain a deeper understanding of the company, its vision, and its potential for Growth.
Urgency – The opportunity to invest in 20/20 GeneSystems on Wefunder ends this Friday.
Big Ambitions – The company has major plans to revolutionize early cancer detection. Find out what’s next!
Prime Time Exposure – Streaming live on e360tv, Facebook, LinkedIn, and YouTube, reaching thousands of impact-focused investors and changemakers like you.
Join us at 6:30 PM Eastern Time for this special episode and be part of the conversation shaping the future of accessible cancer detection.
Imagine a world where cancer screenings are affordable and accessible to all. 20/20 GeneSystems is making that a reality with its innovative multi-cancer early detection technology.
Affordable & Accessible – Their advanced blood test screens for multiple cancers at a fraction of the cost of traditional methods make early detection a routine possibility rather than a luxury.
Detect Cancer While It’s Treatable – Early diagnosis saves lives, and 20/20 GeneSystems’ technology is designed to catch cancer in its earliest, most treatable stages.
Annual Screenings for Everyone – Instead of costly, one-time tests, this technology enables regular, proactive monitoring, helping individuals take charge of their health year after year.
Cutting-Edge AI Integration – Their platform leverages Artificial Intelligence to continuously improve detection accuracy, making it more effective over time.
With a mission to make cancer screening as routine as a cholesterol check, 20/20 GeneSystems is reshaping how we approach early cancer detection—and tomorrow’s show will explore what’s next!
20/20 GeneSystems isn’t just revolutionizing cancer screening—it’s opening new possibilities for widespread early detection that could save countless lives. This is an opportunity to support a company with a powerful mission and a growing impact.
Their Wefunder campaign is coming to a close this Friday, so now is the time to learn more and decide if this opportunity aligns with your investment strategy. While the company’s future looks promising, all investments carry risk, and thoughtful due diligence is essential.
If you believe in supporting breakthrough health technologies that can change lives, visit their Wefunder page to explore their vision, growth potential, and the role they could play in the future of healthcare.
Don’t miss your chance to be part of something transformative! Tune in tomorrow at 6:30 PM ET and consider how you can contribute to the future of accessible cancer screening.
Jonathan Cohen (he/him):
President & CEO, 20/20 GeneSystems
About 20/20 GeneSystems: We develop and commercialize innovative lab tests for the early detection and prevention of cancers and chronic conditions.
Website: www.OneTestforCancer.com
Other URL: wefunder.com/2020.gene.systems
Biographical Information: Jonathan Cohen is a visionary life sciences entrepreneur and executive with extensive experience in the biotechnology and healthcare industries. Throughout his career, Jonathan has succeeded at the intersection of capital formation, start-ups and public policy. As the founding CEO of 20/20 GeneSystems, Inc., he has pioneered groundbreaking initiatives in innovative lab testing for the early detection and prevention of cancers and other diseases. These include co-invention of blood tests w/AI-powered algorithms for the early detection of multiple cancers and chronic inflammation. Jonathan is a longtime advocate for state and federal policies that advance the entrepreneurial life sciences industry.
Linkedin: linkedin.com/in/jonathan-cohen-22574a12/
Originally Published on https://www.superpowers4good.com/
Notifications
